Boehringer will gain access to the de-identified database of Tempus, which comprises clinical, imaging and molecular data.

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

We recently published a list of 10 Firms Crushing the Market. In this article, we are going to take a look at where Tempus AI ...

We’re winding down earnings season, and the old Wall Street adage that “earnings drive stock prices” continues to prove true.

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...

While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.

Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI ...